TLDR
- ABCL stock rose 6.13%, with an earlier intraday jump of 10.3% to $6.53 following Q2 earnings and pipeline news
- Top-line Phase 2 results for ABCL635, a non-hormonal menopause treatment, will be released before market open on August 10
- Q2 revenue fell 76.3% year-over-year to $4.05 million, while net loss widened to $55.4 million
- The company holds $567 million in cash and over $675 million in available liquidity
- Partnerships with Jazz and Vertex have brought in more than $110 million in upfront cash
AbCellera Biologics (ABCL) jumped as much as 10.3% to $6.53 on August 7, closing up 6.13%, as investors reacted to Q2 earnings and an upcoming clinical data release.
AbCellera Biologics Inc., ABCL
The company announced it will release top-line Phase 2 results for ABCL635 before market open on August 10, 2026. An investor call and webcast are scheduled for 4:30 a.m. PT that morning.
ABCL635 is a potential first-in-class non-hormonal antibody targeting the NK3 receptor, designed to reduce the frequency and severity of vasomotor symptoms in postmenopausal women. It entered the clinic in July 2025.
AbCellera to Announce Top-Line Results from the Phase 2 Trial of ABCL635 for the Treatment of Moderate-to-Severe VMS Due to Menopause on Monday, August 10, 2026 https://t.co/iKiCXMLGZe pic.twitter.com/haJhACRwFq
— AbCellera (@AbCelleraBio) August 7, 2026
The Phase 2 trial enrolled approximately 80 postmenopausal women in a randomized, double-blind, placebo-controlled design. It carries the trial identifier NCT07118891.
The data release is the first Phase 2 readout from AbCellera’s GPCR and ion channel platform, making it a closely watched milestone for the company.
Q2 Numbers Tell a Different Story
Q2 financials were weak. Revenue came in at $4.05 million, down 76.3% from $17.08 million in Q2 2025. The net loss widened 59.7% to $55.4 million.
Basic EPS was a loss of $0.18 per share, compared to a loss of $0.12 per share a year ago. Research and development spending reached approximately $46 million in the quarter.
The pipeline did advance. AbCellera now has nine products in Phase 1 and one in Phase 2, compared to 11 in Phase 1 and none in Phase 2 a year ago.
ABCL575 completed Phase 1 dosing, with a readout expected in Q4 2026.
Cash Position Cushions the Burn
Despite the losses, the balance sheet remains a key argument for bulls. The company ended the quarter with $567 million in cash and more than $675 million in total available liquidity.
Partnerships with Jazz Pharmaceuticals and Vertex, focused on T cell engager programs, contributed more than $110 million in upfront cash payments.
Critics note that these are one-time deal payments rather than recurring revenue. Milestones and royalties have not yet scaled to offset ongoing losses.
The most recent analyst rating on ABCL is a Buy, with a $12.00 price target. The stock’s current market cap sits at approximately $1.74 billion.
All eyes now turn to the August 10 data release for ABCL635.
Stop guessing and start investing with confidence. KnockoutStocks gives you the AI insights, market intelligence, and stock research you need to spot opportunities, cut through the noise, and make smarter investment decisions — all in one powerful platform.
Sign up today and get 50% OFF full access to our premium stock picks.
Simply use coupon code SPECIAL50 at checkout to claim your exclusive discount.
